The main objectives of ECCO-2 are: 1) Efficacy: to study whether EQUINACEA ARKOPHARMA, hard
caplets containing cryogenized root of the plant Echinacea purpurea, show an improvement of
the clinical manifestations and disease course in ambulatory patients with covid-19 with a
respiratory presentation and not requiring hospitalization (i.e., mild covid-19). The drug
being evaluated will be added as a supplement of the standard treatment, with its current
recommended dose for treatment of the common cold. 2) Safety: to determine that the incidence
of adverse events is not higher than that seen with the standard treatment applied in each
case.